X4 Pharmaceuticals (XFOR) Total Liabilities (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Total Liabilities for 10 consecutive years, with $97.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 3.55% year-over-year to $97.6 million; the trailing twelve-month figure through Jun 2026 stood at $97.6 million (down 3.55% YoY), and the FY2025 full-year result was $104.2 million, down 16.19% from the prior year.
• Total Liabilities eased to $97.6 million in Q2 2026 per XFOR's latest filing, from $101.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $124.3 million in Q4 2024 and bottomed at $49.9 million in Q1 2022.
• Historically, Total Liabilities has averaged $94.4 million across 5 years, with a median of $101.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 107.8% in 2023, then fell 16.19% in 2025.
• Over 5 years, Total Liabilities stood at $81.5 million in 2022, then climbed by 17.94% to $96.2 million in 2023, then climbed by 29.26% to $124.3 million in 2024, then slipped by 16.19% to $104.2 million in 2025, then declined by 6.3% to $97.6 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $97.6 million, $101.8 million, and $104.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.